Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II (POEMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01451723
Recruitment Status : Terminated (Unusual high frequency of elevated liver function tests.)
First Posted : October 14, 2011
Results First Posted : March 14, 2014
Last Update Posted : March 14, 2014
National Center for Complementary and Integrative Health (NCCIH)
Information provided by (Responsible Party):
Jesus Lovera MD, Louisiana State University Health Sciences Center in New Orleans

Brief Summary:
The hypothesis is that Polyphenon E can protect brain cells in patients with Multiple Sclerosis. To test this hypothesis we are going to compare the changes in n-Acetyl-Aspartate (a chemical that reflects the number of neurons and their metabolism) over one year between people with MS treated with Polyphenon E at a dose of 400mg twice a day and people with MS treated with a matching sugar pill.

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Drug: Polyphenon E Other: Placebo Phase 2

Detailed Description:

This will be a double blind placebo controlled trial of Polyphenon E as a treatment for MS.

The primary outcome will be the changes in NAA levels over one year. Secondary outcomes will be changes in brain atrophy over one year. As an exploratory outcome we will correlate changes in NAA levels with free Plasma levels of EGCG 8 hours after the morning dose.

Exploratory outcomes include disability progression by EDSS, MS functional composite components and a cognitive test battery.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 2 Randomized Placebo Controlled Trial of Polyphenon E in MS
Study Start Date : July 2011
Actual Primary Completion Date : February 2013
Actual Study Completion Date : February 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Polyphenon E 400mg twice a day
Two capsules of Polyphenon E containing 200mg of EGCG each taken twice a day with food.
Drug: Polyphenon E
Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.
Other Names:
  • EGCG
  • epigallocatechin gallate
  • Green tea extract

Placebo Comparator: Placebo
Matching placebo capsules.
Other: Placebo
Matching placebo capsules

Primary Outcome Measures :
  1. Rate of Change in NAA Levels Adjusted for Water Content. [ Time Frame: 1 year ]
    The rate of change will be calculated using all the time points available )baseline, 6 and 12 months) using a mixed model analysis with the Log NAA as the dependent variable and water content, %grey matter, %white matter, %CSF and % lesion volume as covariates. All the voxels available for each subject where estimates have a SD <30 will be used. A spatial anysotropic exponential covariance structure will be used.

Secondary Outcome Measures :
  1. Brain Atrophy [ Time Frame: 1 year ]
    Difference between the two groups in brain atrophy as measured by SIENA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of MS by McDonald criteria
  • Relapsing-remitting MS or secondary progressive MS
  • Stable therapy with Copaxone, Rebif, Betaseron or Avonex 30 mcg for at least six months
  • EDSS Score less than or equal to 7.0
  • Ages 18-60.
  • Participants must have normal organ and marrow function as defined below:

    1. Leukocytes ≥3,000/µL
    2. Absolute neutrophil count ≥1,500/µL
    3. Platelets ≥100,000/µL
    4. Total bilirubin ≤local upper limit of normal
    5. AST (SGOT) ≤local upper limit of normal
    6. ALT (SGPT) ≤local upper limit of normal
    7. Creatinine ≤local upper limit of normal

Exclusion Criteria:

  • MS relapse within the 30 days prior to enrollment
  • A primary progressive form of MS.
  • Previous treatment prior to study entry as follows: complete radiation ablation of the bone marrow or anti-CD4 antibody treatment (Campath) at any time; mitoxantrone, cyclophosphamide, Natalizumab or other immunomodulatory or immunosuppressant therapies except the DMT's included in the inclusion criteria and methylprednisone for relapses within prior nine months.
  • History of renal or liver disease.
  • Consumption of green tea or supplements containing green tea or tea extract within 30 days prior to enrollment.
  • Participants may not participate in any other clinical trial involving investigational agents during the study, or within six months prior to enrolling in the study.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Polyphenon E, tea, or any of the inactive ingredients present in the active or placebo capsules, including gelatin.
  • History of allergic reactions to gadolinium or any other condition contraindicated for MRI.
  • Uncontrolled, clinically-relevant active illness (aside from MS) including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Any condition which would make the subject, in the opinion of the investigator, unsuitable for the study
  • Inability to complete the baseline MRI scan
  • Pregnant women
  • Any underlying predisposition to gastrointestinal bleeding (peptic ulcer disease, gastritis, diverticulitis, colitis, hemorrhoids)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01451723

Layout table for location information
United States, Louisiana
LSu Health Sciences Center
New Orleans, Louisiana, United States, 70112
Sponsors and Collaborators
Louisiana State University Health Sciences Center in New Orleans
National Center for Complementary and Integrative Health (NCCIH)
Layout table for investigator information
Principal Investigator: Jesus F Lovera, MD LSUHSC-New Orleans

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jesus Lovera MD, MD, MsPH, Louisiana State University Health Sciences Center in New Orleans Identifier: NCT01451723    
Other Study ID Numbers: K23AT004433-02 ( U.S. NIH Grant/Contract )
K23AT004433-02 ( U.S. NIH Grant/Contract )
K23AT004433 ( U.S. NIH Grant/Contract )
First Posted: October 14, 2011    Key Record Dates
Results First Posted: March 14, 2014
Last Update Posted: March 14, 2014
Last Verified: January 2014
Keywords provided by Jesus Lovera MD, Louisiana State University Health Sciences Center in New Orleans:
Multiple Sclerosis
Polyphenon E
Green tea
Randomized controlled trial
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Epigallocatechin gallate
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antimutagenic Agents
Anticarcinogenic Agents
Antineoplastic Agents
Neuroprotective Agents